Frank Odds | Academic Influence

Frank Odds's AcademicInfluence.com Rankings

Frank Odds

Biology

#5067

World Rank

#7458

Historical Rank

Microbiology

#198

World Rank

#233

Historical Rank

biology Degrees

Download Badge

Biology

Frank Odds's Degrees

Masters Biology University of Oxford
Bachelors Biology University of Oxford

Similar Degrees You Can Earn

Why Is Frank Odds Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Frank C. Odds was an English mycologist. He studied Candida albicans, establishing how modern researchers study fungal pathogens and the diseases they cause. Early life and education Frank C. Odds was born in Devon, England on August 29, 1945. He studied biochemistry and obtained his undergraduate degree and PhD at the University of Leeds. From 1970 to 1972, Odds was a visiting Fellow at the Center for Disease Control . Returning to the United Kingdom in 1972, Odds accepted a postdoctoral fellowship position back at the University of Leeds until 1975. Odds experienced his first faculty role at the University of Leicester as a lecturer and senior lecture in Medical Microbiology until 1989. After his time at the University of Leicester, Odds became the Director of Bacteriology & Mycology of the Janssen Research Foundation until 1999. His final academic role was Professor of Medical Mycology at the University of Aberdeen before retiring in 2009. Odds died July 7, 2020.

(See a Problem?)

Frank Odds's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. (2008) (4348)
Synergy, antagonism, and what the chequerboard puts between them. (2003) (1872)
Candida and candidosis (1979) (1726)
Antifungal agents: mechanisms of action. (2003) (1015)
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora (1997) (840)
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. (2002) (784)
Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. (2006) (700)
CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species (1994) (683)
Candida orthopsilosis and Candida metapsilosis spp. nov. To Replace Candida parapsilosis Groups II and III (2005) (555)
Granulocytes govern the transcriptional response, morphology and proliferation of Candida albicans in human blood (2005) (467)
Fungal morphogenesis and host invasion. (2002) (460)
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges (2001) (438)
Candida and candidosis: a review and bibliography. 2nd edition. (1988) (426)
NRG1 represses yeast–hypha morphogenesis and hypha‐specific gene expression in Candida albicans (2001) (412)
An insight into the antifungal pipeline: selected new molecules and beyond (2010) (363)
Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. (1999) (334)
Candida infections: an overview. (1987) (307)
Niche-specific regulation of central metabolic pathways in a fungal pathogen (2006) (299)
A triple deletion of the secreted aspartyl proteinase genes SAP4, SAP5, and SAP6 of Candida albicans causes attenuated virulence (1997) (296)
Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence (1997) (291)
Molecular Phylogenetics of Candida albicans (2007) (290)
Correlation of MIC with Outcome for Candida Species Tested against Voriconazole: Analysis and Proposal for Interpretive Breakpoints (2006) (272)
Ectopic Expression of URA3 Can Influence the Virulence Phenotypes and Proteome of Candida albicans but Can Be Overcome by Targeted Reintegration of URA3 at the RPS10 Locus (2004) (271)
Molecular mechanisms of drug resistance in fungi. (1994) (268)
Glycosylphosphatidylinositol-anchored Proteases of Candida albicans Target Proteins Necessary for Both Cellular Processes and Host-Pathogen Interactions* (2006) (262)
Immune Recognition of Candida albicans β-glucan by Dectin-1 (2007) (262)
Resistance of yeasts to azole-derivative antifungals. (1993) (233)
Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi (1997) (232)
Outer Chain N-Glycans Are Required for Cell Wall Integrity and Virulence of Candida albicans* (2006) (221)
Characterization of an azole-resistant Candida glabrata isolate (1992) (218)
Virulence for mice of a proteinase-secreting strain of Candida albicans and a proteinase-deficient mutant. (1983) (218)
Pathogenesis of Candida infections. (1994) (214)
Molecular biological characterization of an azole-resistant Candida glabrata isolate (1997) (210)
Inducible proteinase of Candida albicans in diagnostic serology and in the pathogenesis of systemic candidosis. (1980) (201)
Collaborative Consensus for Optimized Multilocus Sequence Typing of Candida albicans (2003) (194)
Collaborative investigation of variables in susceptibility testing of yeasts (1990) (194)
Outbreak of systemic Candida albicans in intensive care unit caused by cross infection. (1985) (191)
A simple system for the presumptive identification of Candida albicans and differentiation of strains within the species. (1980) (191)
Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo (2011) (190)
One year prospective survey of Candida bloodstream infections in Scotland (2007) (188)
Population Structure and Properties of Candida albicans, as Determined by Multilocus Sequence Typing (2005) (187)
Mnt1p and Mnt2p of Candida albicans Are Partially Redundant α-1,2-Mannosyltransferases That Participate in O-Linked Mannosylation and Are Required for Adhesion and Virulence* (2005) (178)
The Candida albicans CaACE2 gene affects morphogenesis, adherence and virulence (2004) (178)
Interlaboratory Comparison of Results of Susceptibility Testing with Caspofungin against Candida and Aspergillus Species (2004) (177)
Recognition and Blocking of Innate Immunity Cells by Candida albicans Chitin (2011) (175)
Candida albicans Pmr1p, a Secretory Pathway P-type Ca2+/Mn2+-ATPase, Is Required for Glycosylation and Virulence* (2005) (174)
Immune recognition of Candida albicans beta-glucan by dectin-1. (2007) (169)
Morphogenesis in Candida albicans. (1985) (167)
Candida dubliniensis candidemia in patients with chemotherapy-induced neutropenia and bone marrow transplantation. (1999) (160)
Genetic similarity and maintenance of Candida albicans strains from a group of AIDS patients, demonstrated by DNA fingerprinting (1992) (159)
Glucose promotes stress resistance in the fungal pathogen Candida albicans. (2009) (157)
Prevalence of Candida dubliniensis Isolates in a Yeast Stock Collection (1998) (156)
Evaluation of Possible Correlations between Antifungal Susceptibilities of Filamentous Fungi In Vitro and Antifungal Treatment Outcomes in Animal Infection Models (1998) (155)
Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. (1996) (154)
Temporal events in the intravenous challenge model for experimental Candida albicans infections in female mice (2005) (151)
Molecular analysis of CaMnt1p, a mannosyl transferase important for adhesion and virulence of Candida albicans. (1998) (149)
Animal models of mucosal Candida infection. (2008) (148)
Infection-related gene expression in Candida albicans. (2007) (147)
Property Differences among the Four Major Candida albicans Strain Clades (2009) (145)
Sequence of the Candida albicans gene encoding the secretory aspartate proteinase. (1991) (142)
New targets and delivery systems for antifungal therapy. (2000) (140)
Candida albicans Strain Maintenance, Replacement, and Microvariation Demonstrated by Multilocus Sequence Typing (2006) (140)
Multilocus Sequence Typing of the Pathogenic Fungus Aspergillus fumigatus (2007) (140)
Loss of Cell Wall Mannosylphosphate in Candida albicans Does Not Influence Macrophage Recognition* (2004) (134)
Application of DNA typing methods to Candida albicans epidemiology and correlations with phenotype. (1990) (133)
Optimization and Validation of Multilocus Sequence Typing for Candida albicans (2003) (132)
Mechanisms and clinical impact of antifungal drug resistance. (1994) (130)
Multilocus Sequence Typing for Differentiation of Strains of Candida tropicalis (2005) (129)
Developmental Regulation of an Adhesin Gene during Cellular Morphogenesis in the Fungal Pathogen Candida albicans (2007) (127)
Niche-Specific Activation of the Oxidative Stress Response by the Pathogenic Fungus Candida albicans (2007) (127)
Multilocus Sequence Typing of Pathogenic Candida Species (2008) (121)
Endoplasmic Reticulum α-Glycosidases of Candida albicans Are Required for N Glycosylation, Cell Wall Integrity, and Normal Host-Fungus Interaction (2007) (121)
GFP as a quantitative reporter of gene regulation in Candida albicans (2004) (119)
Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro (1982) (118)
Molecular phylogenetics and epidemiology of Candida albicans. (2010) (115)
Genetic Dissection of Azole Resistance Mechanisms in Candida albicans and Their Validation in a Mouse Model of Disseminated Infection (2010) (115)
A morphology index for characterization of cell shape in Candida albicans. (1989) (114)
Exposure of Candida albicans to antifungal agents affects expression of SAP2 and SAP9 secreted proteinase genes. (2005) (106)
A Multifunctional Mannosyltransferase Family in Candida albicans Determines Cell Wall Mannan Structure and Host-Fungus Interactions* (2010) (104)
Genome-wide analysis of Candida albicans gene expression patterns during infection of the mammalian kidney (2009) (98)
Candida concentrations in the vagina and their association with signs and symptoms of vaginal candidosis. (1988) (95)
The Mnn2 Mannosyltransferase Family Modulates Mannoprotein Fibril Length, Immune Recognition and Virulence of Candida albicans (2013) (95)
Peroxisomal Fatty Acid β-Oxidation Is Not Essential for Virulence of Candida albicans (2006) (94)
Biochemical Tests for Identification of Medical Bacteria (1981) (92)
Laboratory evaluation of antifungal agents: a comparative study of five imidazole derivatives of clinical importance. (1980) (91)
Modification and extension of tests for differentiation of Candida species and strains. (1983) (91)
Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation (1995) (91)
The Evolutionary Rewiring of Ubiquitination Targets Has Reprogrammed the Regulation of Carbon Assimilation in the Pathogenic Yeast Candida albicans (2012) (90)
Antifungal effects of fluconazole (UK 49858), a new triazole antifungal, in vitro. (1986) (89)
Fungal virulence studies come of age (2001) (85)
Use of specialised isolation media for recognition and identification ofCandida dubliniensis isolates from HIV-infected patients (1997) (84)
An examination of the production of hydrolytic enzymes and toxins by pathogenic strains of Candida albicans. (1971) (83)
Nomenclature of fungal diseases: a report and recommendations from a Sub-Committee of the International Society for Human and Animal Mycology (ISHAM). (1992) (83)
Cell wall glycans and soluble factors determine the interactions between the hyphae of Candida albicans and Pseudomonas aeruginosa (2008) (82)
The activity in vitro and in vivo of a new imidazole antifungal, ketoconazole. (1980) (81)
Survival in experimental Candida albicans infections depends on inoculum growth conditions as well as animal host. (2000) (79)
Early-Expressed Chemokines Predict Kidney Immunopathology in Experimental Disseminated Candida albicans Infections (2009) (77)
Strain Typing and Determination of Population Structure of Candida krusei by Multilocus Sequence Typing (2006) (77)
Epidemiology of Candida Infections in Aids (1990) (74)
Melanin Externalization in Candida albicans Depends on Cell Wall Chitin Structures (2010) (74)
Genetic evidence for recombination in Candida albicans based on haplotype analysis. (2004) (74)
Effects of imidazole- and triazole-derivative antifungal compounds on the growth and morphological development of Candida albicans hyphae. (1985) (73)
Candida albicans proteinase as a virulence factor in the pathogenesis of Candida infections. (1985) (73)
Virulence of an aspergillopepsin-deficient mutant of Aspergillus fumigatus and evidence for another aspartic proteinase linked to the fungal cell wall. (1997) (72)
European expert opinion on the management of invasive candidiasis in adults. (2011) (71)
Efficacy of Caspofungin and Voriconazole Combinations in Experimental Aspergillosis (2005) (70)
Candida albicans genome sequence: a platform for genomics in the absence of genetics (2004) (70)
Academic selection criteria and subsequent performance (1990) (69)
Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents. (1984) (69)
Influences of Methodological Variables on Susceptibility Testing of Caspofungin against Candida Species and Aspergillus fumigatus (2003) (68)
Dimorphic Fungi in Biology and Medicine (2012) (67)
Global Role of the Protein Kinase Gcn2 in the Human Pathogen Candida albicans (2005) (66)
Enzyme activities associated with carbohydrate synthesis and breakdown in the yeast and mycelial forms of Candida albicans. (1973) (64)
Multilocus Sequence Typing for Analyses of Clonality of Candida albicans Strains in Taiwan (2006) (64)
Antifungal susceptibility testing of Candida spp. by relative growth measurement at single concentrations of antifungal agents (1992) (63)
Purified Candida albicans proteinase in the serological diagnosis of systemic candidosis. (1980) (62)
Increased Sensitivity of Mannanemia Detection Tests by Joint Detection of α- and β-Linked Oligomannosides during Experimental and Human Systemic Candidiasis (2004) (62)
Purification and Properties of a Glycoprotein Acid Phosphatase from Candida albicans (1973) (61)
Analysis of Candida albicans phenotypes from different geographical and anatomical sources (1983) (60)
Optimum conditions for initiation of filamentation in Candida albicans. (1975) (60)
Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates (1996) (59)
Antifungal activity of itraconazole compared with hydroxy-itraconazole in vitro. (2000) (59)
Chitinase levels in guinea pig blood are increased after systemic infection with Aspergillus fumigatus. (1996) (59)
The antiinflammatory effects of ketoconazole. A comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea-pigs. (1991) (58)
Binding of plasma proteins to Candida species in vitro. (1988) (57)
Contribution of mutations in the cytochrome P 450 14 α-demethylase ( Erg 11 p , Cyp 51 p ) to azole resistance in Candida albicans (1999) (56)
Relevance of Antigenicity of Candida Albicans Growth Phases to Diagnosis of Systemic Candidiasis (1973) (53)
Prevalence of pathogenic yeasts and humoral antibodies to candida in diabetic patients. (1978) (52)
Candida albicans GRX2, encoding a putative glutaredoxin, is required for virulence in a murine model. (2007) (51)
Effects of azole antifungals in vitro on host/parasite interactions relevant to Candida infections. (1988) (51)
Principles and practice of clinical mycology (1996) (51)
Quality control guidelines for National Committee for Clinical Laboratory Standards--recommended broth macrodilution testing of ketoconazole and itraconazole (1996) (51)
MAPKKK-independent Regulation of the Hog1 Stress-activated Protein Kinase in Candida albicans* (2011) (51)
Resistance of clinically important yeasts to antifungal agents. (1996) (50)
Pyrosequencing Analysis of 20 Nucleotides of Internal Transcribed Spacer 2 Discriminates Candida parapsilosis, Candida metapsilosis, and Candida orthopsilosis (2009) (50)
"Room temperature" use of CHROMagar Candida. (2000) (49)
Candida albicans Iff11, a Secreted Protein Required for Cell Wall Structure and Virulence (2007) (49)
Epidemiology of vaginal Candida infection: significance of numbers of vaginal yeasts and their biotypes. (1987) (48)
Genomics, molecular targets and the discovery of antifungal drugs. (2005) (47)
Accumulation of 3-Ketosteroids Induced by Itraconazole in Azole-Resistant Clinical Candida albicans Isolates (1999) (45)
The variability of creatinine excretion in normal subjects, mental patients and pregnant women. (1969) (44)
Interactions of Candida albicans yeast cells, germ tubes and hyphae with human polymorphonuclear leucocytes in vitro. (1984) (44)
Glycosylation status of the C. albicans cell wall affects the efficiency of neutrophil phagocytosis and killing but not cytokine signaling (2011) (44)
Improved method for estimation of azole antifungal inhibitory concentrations against Candida species, based on azole/antibiotic interactions. (1986) (43)
Antifungal agents: their diversity and increasing sophistication (2003) (43)
The effect of growth medium of filament production in Candida albicans. (1974) (43)
Epidemiological shifts in opportunistic and nosocomial Candida infections: mycological aspects. (1996) (42)
Biotyping of Candida albicans: results of an international collaborative survey (1989) (42)
In Vitro and In Vivo Activities of the Novel Azole Antifungal Agent R126638 (2004) (41)
Functional analysis of the phospholipase C gene CaPLC1 and two unusual phospholipase C genes, CaPLC2 and CaPLC3, of Candida albicans. (2005) (41)
Ectopic Expression of URA 3 Can Influence the Virulence Phenotypes and Proteome of Candida albicans but Can Be Overcome by Targeted Reintegration of URA 3 at the RPS 10 Locus (2004) (41)
Switch of phenotype as an escape mechanism of the intruder (1997) (41)
Different Consequences of ACE2 and SWI5 Gene Disruptions for Virulence of Pathogenic and Nonpathogenic Yeasts (2006) (41)
Mixed Candida albicans strain populations in colonized and infected mucosal tissues (2008) (40)
Carriage of Candida species and C albicans biotypes in patients undergoing chemotherapy or bone marrow transplantation for haematological disease. (1989) (40)
Development of Candida albicans hyphae in different growth media--variations in growth rates, cell dimensions and timing of morphogenetic events. (1986) (40)
Candida strains from neonates in a special care baby unit. (1992) (40)
Carnitine-Dependent Transport of Acetyl Coenzyme A in Candida albicans Is Essential for Growth on Nonfermentable Carbon Sources and Contributes to Biofilm Formation (2008) (39)
Ecology and epidemiology of Candida species. (1984) (38)
Neonatal systemic candidiasis treated with miconazole. (1980) (38)
The Novel Azole R126638 Is a Selective Inhibitor of Ergosterol Synthesis in Candida albicans, Trichophyton spp., and Microsporum canis (2004) (38)
The anti‐Malassezia furfur activity in vitro and in experimental dermatitis of six imidazole antifungal agents: bifonazole, clotrimazole, flutrimazole, ketoconazole, miconazole and sertaconazole (1995) (38)
Susceptibility testing of pathogenic fungi with itraconazole: a process analysis of test variables. (2001) (36)
Cross‐sectional study of oral Candida carriage in a human immunodeficiency virus (HIV)‐seropositive population: predisposing factors, epidemiology and antifungal susceptibility (1998) (36)
Control of an outbreak of systemic Candida albicans. (1985) (35)
Distribution of pathogenic yeasts and humoral antibodies to candida among hospital inpatients. (1980) (35)
Activities of an Intravenous Formulation of Itraconazole in Experimental Disseminated Aspergillus, Candida, and Cryptococcus Infections (2000) (35)
Need for Early Antifungal Treatment Confirmed in Experimental Disseminated Candida albicans Infection (2004) (35)
Drug evaluation: BAL-8557--a novel broad-spectrum triazole antifungal. (2006) (34)
Characterization of Candida isolates from pediatric burn patients (1988) (34)
Peptones and mycological reproducibility. (1978) (33)
Relative inhibition factors--a novel approach to the assessment of antifungal antibiotics in vitro. (1984) (33)
Antifungal activity of saperconazole (R 66 905) in vitro. (1989) (33)
Multilocus sequence typing of Candida albicans isolates from animals. (2008) (33)
Oxygen as limiting nutrient for growth of Cryptococcus neoformans (1995) (32)
Detection of Candida precipitins. a comparison of double diffusion and counter immunoelectrophoresis. (1975) (31)
Candida albicans and Candida dubliniensis Respond Differently to Echinocandin Antifungal Agents In Vitro (2007) (31)
Pathogenic fungi in the 21st century. (2000) (30)
Sordarin antifungal agents (2001) (30)
Candida albicans strain types from the genitalia of patients with and without Candida infection. (1983) (30)
Systemic candidiasis in Spanish heroin addicts: a possible source of infection. (1987) (30)
New Clox Systems for Rapid and Efficient Gene Disruption in Candida albicans (2014) (30)
In Candida albicans, resistance to flucytosine and terbinafine is linked to MAT locus homozygosity and multilocus sequence typing clade 1. (2009) (30)
Laboratory methods for flucytosine (5-fluorocytosine) (1984) (29)
Functional aspects of secreted Candida proteinases. (1998) (29)
Disseminated Candida infection syndrome in heroin addicts--dominance of a single Candida albicans biotype. (1987) (29)
Cure and Relapse with Antifungal Therapy (1977) (29)
Biotyping of medically important fungi. (1985) (28)
Distribution of chitinase in guinea pig tissues and increases in levels of this enzyme after systemic infection with Aspergillus fumigatus. (1999) (27)
Quantitative microculture system with standardized inocula for strain typing, susceptibility testing, and other physiologic measurements with Candida albicans and other yeasts (1991) (27)
Synthesis and in vitro and in vivo structure-activity relationships of novel antifungal triazoles for dermatology. (2005) (27)
Isolation of Candida species on media with and without added fluconazole reveals high variability in relative growth susceptibility phenotypes (1997) (26)
Toward a molecular understanding of Candida albicans virulence. (2006) (26)
Activity of cilofungin (LY121019) against Candida species in vitro. (1988) (26)
Candida species and C. albicans biotypes in women attending clinics in genitourinary medicine. (1989) (25)
Candida and Torulopsis: a blinded evaluation of use of pseudohypha formation as basis for identification of medically important yeasts (1997) (25)
Typing of Candida albicans strains. (1992) (25)
Candida albicans, the life and times of a pathogenic yeast. (2009) (25)
Growth of pathogenic Candida isolates anaerobically and under elevated concentrations of CO2 in air. (1987) (25)
Intraconazole--a new oral antifungal agent with a very broad spectrum of activity in superficial and systemic mycoses. (1993) (24)
Novel antifungals based on 4-substituted imidazole: a combinatorial chemistry approach to lead discovery and optimization. (2000) (24)
Increased sensitivity of mannanemia detection tests by joint detection of alpha- and beta-linked oligomannosides during experimental and human systemic candidiasis. (2004) (24)
Arthritis without grains caused by Pseudallescheria boydii (1995) (24)
Comparison of Candida albicans strain types among isolates from three countries. (2008) (23)
Should resistance to azole antifungals in vitro be interpreted as predicting clinical non-response? (1998) (22)
Single allele knock-out of Candida albicans CGT1 leads to unexpected resistance to hygromycin B and elevated temperature. (2000) (22)
Correlation of susceptibility test results in vitro with response in vivo: ketoconazole therapy in a systemic candidiasis model. (1985) (21)
Multilocus sequence typing confirms synonymy but highlights differences between Candida albicans and Candida stellatoidea. (2008) (21)
Colony Variations in Candida Species (1989) (21)
Expression of an epitope by surface glycoproteins of Candida albicans. Variability among species, strains and yeast cells of the genus Candida. (1990) (20)
Bioassays for itraconazole blood levels: an interlaboratory collaborative study. (1999) (20)
Secreted proteinases and Candida albicans virulence. (2008) (20)
Role of the Candida albicans MNN1 gene family in cell wall structure and virulence (2013) (20)
Mitochondrial haplotypes and recombination in Candida albicans. (2008) (19)
Problems in the laboratory assessment of antifungal activity. (1979) (19)
Influence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs. (2002) (19)
Resistance of the Candida albicans filamentous cycle to environmental change. (1975) (19)
Potential for Penetration of Passive Barriers to Fungal Invasion in Humans (1991) (19)
Molecular phylogenetic analysis of Candida tropicalis isolates by multi-locus sequence typing. (2008) (19)
Azole antifungals induce up-regulation of SAP4, SAP5 and SAP6 secreted proteinase genes in filamentous Candida albicans cells in vitro and in vivo. (2007) (18)
FLUCONAZOLE VERSUS KETOCONAZOLE IN OROPHARYNGEAL CANDIDIASIS IN AIDS (1989) (18)
Candida albicans: fundamental research on an opportunistic human pathogen. (2009) (17)
Identification of Candida glabrata by a 30-Second Trehalase Test (2002) (17)
Multiple functions of DOA1 in Candida albicans. (2007) (17)
Effects of temperature on anti-Candida activities of antifungal antibiotics (1993) (17)
Novel antifungals based on 4-substituted imidazole: solid-phase synthesis of substituted aryl sulfonamides towards optimization of in vitro activity. (2000) (17)
Nomenclature of fungal diseases (1992) (16)
Reflections on the question: what does molecular mycology have to do with the clinician treating the patient? (2003) (16)
Differential Regulation of Kidney and Spleen Cytokine Responses in Mice Challenged with Pathology-Standardized Doses of Candida albicans Mannosylation Mutants (2010) (16)
Long-term laboratory preservation of pathogenic yeasts in water. (1991) (15)
Reaction of Candida albicans cells of different morphology index with monoclonal antibodies specific for the hyphal form. (1991) (14)
In Vitro and In Vivo Activities of the Novel Azole Antifungal Agent R 126638 (2004) (14)
Personal opinion: Can antifungal sensitivity tests predict clinical treatment outcomes? (1997) (14)
Non-identity and authentication of two major reference strains of Candida albicans. (1991) (13)
Candida Infections in AIDS Patients (1992) (13)
Suppression of ATP in Candida albicans by imidazole and derivative antifungal agents. (1985) (13)
Fluconazole plus amphotericin B combinations are not contraindicated and may add benefit for the treatment of candidemia. (2003) (13)
Mycology in oral pathology. (1997) (11)
Expansion of the Candida albicans cell envelope in different morphological forms of the fungus. (1992) (10)
Quantification of Candida albicans morphology in vaginal smears. (1991) (10)
The Candida albicans pH-regulated KER1 gene encodes a lysine/glutamic-acid-rich plasma-membrane protein that is involved in cell aggregation. (2004) (10)
Practical Laboratory Mycology (3rd edition) (1986) (9)
Effect of chitinase complex on the antigenicity and chemistry of yeast-form cell walls and other fractions of Histoplasma capsulatum and Blastomyces dermatitidis. (1974) (9)
Persistence of miconazole in vaginal secretions after single applications. Implications for the treatment of vaginal candidosis. (1981) (9)
Susceptibilities of Candida spp. to antifungal agents visualized by two-dimensional scatterplots of relative growth (1996) (8)
Pathogenesis of invasive candidiasis. (1994) (8)
Differential and enrichment media for selective culture and recognition of yeast species from clinical material (1995) (8)
Clonality structure in Candida dubliniensis. (2002) (8)
Standardization of antigens from Aspergillus fumigatus. (1983) (8)
New advances in antifungal treatment. (2000) (8)
Relevance ofAntigenicity ofCandida Albicans GrowthPhases toDiagnosis ofSystemic Candidiasis (1973) (7)
Editorial: Resistance to antifungal agents. (2010) (7)
Demonstration of a septal pore in budding Candida albicans yeast cells. (1984) (7)
Effects of itraconazole on phagocytosis and killing of Candida glabrata by polymorphonuclear leucocytes from guinea pigs. (1992) (7)
Acid phosphatase levels in the genus Candida and their application to the taxonomy and identification of pathogenic Candida species. (1974) (6)
Pathogenic fungi in the 21 st century (6)
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. (2006) (6)
A one minute' trehalase detection test for the identification of Candida glabrata (2001) (6)
Might Candida albicans be made to mate after all? (2000) (6)
Numerical taxonomic analysis of imperfect yeast species in Candida and Torulopsis shows no basis for generic separation. (1990) (6)
Fungal morphology after treatment with itraconazole as a single oral dose in experimental vaginal candidosis in rats. (1991) (6)
Abrogation by glucose of the ATP suppression induced by miconazole in Candida albicans. (1989) (6)
[What functions do six different genes for secretory proteinases have in Candida albicans?]. (1998) (5)
Consistency of protein patterns in Candida albicans during hyphal septum and branch formation. (1986) (5)
Multiple functions of DOA 1 in Candida albicans (2007) (5)
Efficacy of parenteral itraconazole against disseminated Candida albicans infection in two mouse strains. (2002) (5)
Reporters for the analysis of N-glycosylation in Candida albicans☆ (2013) (5)
Routine use of modified Sabouraud's dextrose broth in the germ tube test for Candida albicans. (1975) (4)
Coccidioidomycosis: flying conidia and severed heads (2003) (4)
Fungal morphology after treatment with itraconazole as a single oral dose in experimental vaginal candidosis in rats (1991) (4)
Synthesis and in vitro and in vivo Antifungal Activity of the Hydroxy Metabolites of Saperconazole (2010) (4)
Diagnosis and treatment of human mycoses (2008) (4)
Finger nails as a reservoir for Candida albicans in recurrence of vaginal candidosis. (1986) (4)
Commercial Kits for Yeast Identification: Concerns for Standardisation (2001) (4)
[Identification, cloning and characterization of the gene for the secretory aspartate protease of Candida albicans]. (1991) (3)
[Recent advances in the biology of Candida]. (1987) (3)
Antifungal Agents: Resistance and Rational Use (2005) (3)
Safety aspects of working with Candida albicans-infected mice. (2004) (3)
Quinoline derivatives and their use as inhibitors mycobacterial (2003) (3)
Correction for Sandai et al., The Evolutionary Rewiring of Ubiquitination Targets Has Reprogrammed the Regulation of Carbon Assimilation in the Pathogenic Yeast Candida albicans (2015) (2)
Niche-Speciﬁc Activation of the Oxidative Stress Response by the Pathogenic Fungus Candida albicans (cid:1) (2007) (2)
USE OF SPECIALISED ISOLATION MEDIA FOR RECOGNITION AND IDENTIFICATION OF C. DUBLINIENSIS FROM HIV-INFECTED PATIENTS (1999) (2)
Prevalence ofpathogenic yeasts andhumoral antibodies tocandida indiabetic patients (1978) (1)
Evolution of Pathogenic Candida Species (2008) (1)
Pyrosequencing ® analysis of 20 nucleotides of the 1 Internal Transcribed Spacer 2 discriminates 2 Candida parapsilosis , Candida metapsilosis and 3 Candida orthopsilosis (2009) (1)
Morphological Change in Candida albicans. (1993) (1)
KETOCONAZOLE RESISTANCE (1982) (1)
Laboratory Evaluation of Antifungal Agents in Vitro (1994) (1)
Vulvovaginal Candida infection: current perspectives (1993) (1)
Role of the Candida albicans MNN1 gene family in cell wall structure and virulence (2013) (1)
Antifungal combinations: where do we stand? (2006) (1)
“CHRONIC CANDIDIASIS” AND CONFUSION IN MEDICINE (2002) (0)
Are Molecular Methods the Optimum Route to Antimicrobial Drugs (2008) (0)
JPBURNIE, FC ODDS W LEE, C WEBSTER, J D WILLIAMS (2015) (0)
[Relative inhibition factors: a new approach to the evaluation of antifungal antibiotics in vitro]. (1989) (0)
Compositions contenant un antifongique et un agent cationique (1998) (0)
SABOURAUDIA Journal of the International Society for Human and Animal Mycology (2000) (0)
A three day mouse model of Candida albicans infection outcome (2011) (0)
Does Candida Albicans Play a Role in the Etiology of Endometriosis? (2013) (0)
Book Review: Fungal Infection in the Compromised Patient (1991) (0)
Professor Emly Glyn Vaughan Evans 4th October 1941-4th August 2003. (2003) (0)
S027 Biology of Candida in the vaginal Candida context (1997) (0)
Professor Emlyn Glyn Vaughan Evans (2003) (0)
Differential regulation of kidney and spleen cytokine responses in mice infected with a Candida albicans mannosylation mutant (2011) (0)
Contents to volume 23 (1985) (1985) (0)
[Changes in epidemiology of opportunistic infections due to Candida]. (1995) (0)
Minutes of the annual meeting of the Belgian Society for Human and Animal Mycology (14 March 1992). (1992) (0)
XII. Human Fungal Pathogens, Judith E. Domer, George S. Kobayashi (Eds.). Springer-Verlag, Berlin (2003 [‘2004’]), xvii, Pp. xvii + 376, figures 34, tables 31. ISBN 3 540 42629 9. Price €169.95, US $189, £130.50. (2004) (0)
A method for use of compositions which contain dichlorophenyl to treat seborrheic dermatitis, dandruff, psoriasis and acne, and compositions thereof, (1998) (0)
Water-soluble antifungal azoles (1996) (0)
Epidemiology of Vaginal Candida Infection: Significance of Numbers of Vaginal Yeasts and Their Biotypes (1987) (0)
Problems inthelaboratory assessment ofantifungal activity (1979) (0)
Quantification of Candida Morphology in Vitro and in Vivo (1993) (0)
Normal Host-Fungus Interaction Glycosylation , Cell Wall Integrity , and Are Required for N Candida albicans-Glycosidases of α Endoplasmic Reticulum (2007) (0)
Water-soluble azole antifungal (1995) (0)
Book review (2004) (0)
Molecular biology in the study of Candida. (1990) (0)
Substituted atsolonijohdannaisia for the treatment of diseases caused by Helicobacter (1995) (0)
New approaches for antifungal drugs: edited by Prabhavathi B. Fernandes Birkhäuser, 1992. Sw. Fr. 128.00 (ix + 201 pages) ISBN 0 8176 3602 1 (1993) (0)
Azole antifungals soluble in water. (1995) (0)
Perspective of the Application of Molecular Biology Techniques in the Study of Candida (1991) (0)
Quinoline derivatives and their use as inhibitors of mycobacteria. (2003) (0)
A tool for analysis of N-glycosylation in Candida albicans (2009) (0)
Scientific study of Candida albicans infections (1995) (0)
2,4,4-tri-substituted-1,3-dioxolane fungicidal (1998) (0)
[Antifungal agent resistance of yeasts of clinical significance]. (1995) (0)
Contents of Volume 23, 1985 (1985) (0)
Purification andProperties ofa Glycoprotein AcidPhosphatase fromCandida albicans (1973) (0)
In Vivo albicans Confers Echinocandin Resistance Elevated Cell Wall Chitin in Candida (2011) (0)
InCandidaalbicans, resistance to£ucytosineand terbina¢ne is linked toMAT locushomozygosityandmultilocus sequence typing clade1 (2009) (0)
University of Birmingham The Mnn2 mannosyltransferase family modulates mannoprotein fibril length, immune recognition and virulence of Candida albicans (2013) (0)
Antifongiques 1,3-dioxolane trisubstitues en 2,4,4 (1998) (0)
[Predominance of Candida albicans serotype A, biotype 15 3/7 in outbreaks of disseminated candidiasis in heroin addicts in Spain]. (1987) (0)
Laboratory Evaluation of Anifungal Agents in Vitro (1994) (0)
Clinical Mycology, 2nd edn, Elias Anaissie, Michael McGinnis, Michael Pfaller. Chunrchill Livingstone (2009), Pp 700. £116·40., ISBN: 978-1-4160-5680-5 (2009) (0)
FOCUS Antifungal Susceptibility Testing: Practical Aspects and Current Challenges (2001) (0)
Compositions containing an antifungal agent and a cationic. (1998) (0)

This paper list is powered by the following services:

Other Resources About Frank Odds

en.wikipedia.org

What Schools Are Affiliated With Frank Odds?

Frank Odds is affiliated with the following schools: